XERIS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $2.05 per share for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-08.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2024-11-08
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.94, a 10.60% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2023-03-31 was $2.17, a 22.78% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2022-03-31 was $2.81.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $1.64, a 43.45% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $2.90, a 41.30% decline from fiscal 2021.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2021 was $4.94.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2024-09-30 | $2.05 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | $2.02 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $1.94 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $1.64 10-K · filed 2024-03-06 | |||
| 2023-09-30 | $1.68 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.75 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $2.17 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $2.90 10-K · filed 2024-03-06 | |||
| 2022-09-30 | $2.94 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $2.84 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $2.81 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $4.94 10-K · filed 2022-03-11 | |||
| 2021-09-30 | $5.38 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |